Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1677882 | 0.95 | P2RX7 (0.43) | P2RX7SMN1; SMN2ALDH1A1CYP19A1CYP17A1 | |
| SCHEMBL1677501 | 0.95 | P2RX7 (0.43) | P2RX7SMN1; SMN2ALDH1A1CYP19A1CYP17A1 | |
| SCHEMBL1678272 | 0.94 | P2RX7 (0.43) | P2RX7SMN1; SMN2ALDH1A1CYP19A1CYP17A1 | |
| SCHEMBL1678436 | 0.92 | P2RX7 (0.51) | P2RX7SMN1; SMN2ALDH1A1CYP19A1CYP17A1 | |
| SCHEMBL1678321 | 0.91 | P2RX7 (0.45) | P2RX7SMN1; SMN2ALDH1A1CYP19A1CYP17A1 | |
| Hydrochloric Acid SCHEMBL1677912 | 0.91 | P2RX7 (0.50) | P2RX7SMN1; SMN2ALDH1A1CYP19A1CYP17A1 | |
| SCHEMBL1678506 | 0.87 | P2RX7 (0.46) | P2RX7SMN1; SMN2ALDH1A1CYP19A1CYP17A1 | |
| SCHEMBL1677703 | 0.87 | P2RX7 (0.46) | P2RX7SMN1; SMN2ALDH1A1CYP19A1CYP17A1 | |
| SCHEMBL1677712 | 0.86 | P2RX7 (0.44) | P2RX7SMN1; SMN2ALDH1A1CYP19A1CYP17A1 | |
| SCHEMBL1677498 | 0.86 | P2RX7 (0.46) | P2RX7SMN1; SMN2ALDH1A1CYP19A1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901155-B2 | Method for treating a TRPV1-mediated disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-12-02 | — | — | US | claimed |
| EP-2666767-A1 | Therapeutic agent for TRPV1-mediated disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-11-27 | — | — | EP | claimed |
| EP-2210878-B1 | THERAPEUTIC AGENT FOR OVERACTIVE BLADDER | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-07-31 | — | — | EP | claimed |
| US-20130090359-A1 | METHOD FOR TREATING A TRPV1-MEDIATED DISEASE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-11 | — | — | US | claimed |
| US-20110201655-A1 | PHARMACEUTICAL COMPOSITION IMPROVING INTESTINAL ABSORPTION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-08-18 | — | — | US | claimed |
| EP-2351566-A1 | PHARMACEUTICAL COMPOSITION IMPROVED IN ABSORPTION THROUGH INTESTINAL TRACT | Santen Pharmaceutical Co., Ltd (JP) | 2011-08-03 | — | — | EP | claimed |
| US-20100261911-A1 | THERAPEUTIC AGENT FOR TRPV1-MEDIATED DISEASE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | claimed |
| EP-2210878-A1 | THERAPEUTIC AGENT FOR TRPV1-MEDIATED DISEASE | Santen Pharmaceutical Co., Ltd (JP) | 2010-07-28 | — | — | EP | claimed |
| EP-1743885-A2 | TNF-Alpha Produktion Hemmer zur Behandlung von Autoimmunerkrankungen | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-01-17 | — | — | EP | claimed |
| US-7098226-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-08-29 | — | — | US | claimed |
| EP-1302461-A1 | TNF-ALPHA PRODUCTION INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | claimed |
| US-20030032623-A1 | Tnf-alpha production inhibitors | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2003-02-13 | — | — | US | claimed |
| US-20190038573-A1 | ION CHANNEL ACTIVATORS AND METHODS OF USE | CLIFF-CARTWRIGHT CORPORATION | 2019-02-07 | — | — | US | disclosed |
| EP-3131541-A1 | ION CHANNEL ACTIVATORS AND METHODS OF USE | Flex Pharma, Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20170042834-A1 | ION CHANNEL ACTIVATORS AND METHODS OF USE | CLIFF-CARTWRIGHT CORPORATION | 2017-02-16 | — | — | US | disclosed |
| WO-2015160843-A1 | ION CHANNEL ACTIVATORS AND METHODS OF USE | FLEX PHARMA, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| US-7098226-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20050014800-A1 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1302461-A1 | TNF-ALPHA PRODUCTION INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-20030032623-A1 | Tnf-alpha production inhibitors | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201655-A1 | PHARMACEUTICAL COMPOSITION IMPROVING INTESTINAL ABSORPTION | SLC10A2, NR1H4, SLC10A6 | P2RX7 1697/4885SMN1; SMN2 4040/4885ALDH1A1 2063/4885 |
| US-20050014800-A1 | Angiogenesis inhibitor | FLT4, KDR, FLT1 | P2RX7 1805/4885SMN1; SMN2 4717/4885ALDH1A1 1011/4885 |
| US-20100261911-A1 | THERAPEUTIC AGENT FOR TRPV1-MEDIATED DISEASE | TRPV1, TRPA1, TRPV3 | P2RX7 164/4885SMN1; SMN2 3244/4885ALDH1A1 1878/4885 |
| US-20130090359-A1 | METHOD FOR TREATING A TRPV1-MEDIATED DISEASE | TRPV1, TRPV3, TRPV2 | P2RX7 256/4885SMN1; SMN2 2303/4885ALDH1A1 1536/4885 |
| US-20030032623-A1 | Tnf-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | P2RX7 2242/4885SMN1; SMN2 4171/4885ALDH1A1 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.